Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Synthekine Secures $100M Series C Financing

2023-01-06
MENLO PARK, CA, Synthekine Inc., an engineered cytokine therapeutics company, announced the closing of a $100 million Series C financing.
Synthekine Inc., an engineered cytokine therapeutics company, announced the closing of a $100 million Series C financing led by The Column Group, with participation from both new and existing investors.

Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors